(0.23%) 5 111.59 points
(0.34%) 38 369 points
(0.27%) 15 971 points
(-1.29%) $82.77
(6.34%) $2.05
(-0.09%) $2 345.20
(-0.27%) $27.46
(3.95%) $958.55
(-0.22%) $0.933
(-0.33%) $10.99
(-0.54%) $0.796
(1.65%) $93.39
-0.76% INR 1 071.10
Live Chart Being Loaded With Signals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally...
Stats | |
---|---|
Dagens volum | 442 799 |
Gjennomsnittsvolum | 1.24M |
Markedsverdi | 302.25B |
EPS | INR-12.45 ( 2024-02-15 ) |
Neste inntjeningsdato | ( INR7.93 ) 2024-05-15 |
Last Dividend | INR2.50 ( 2023-09-18 ) |
Next Dividend | INR0 ( N/A ) |
P/E | -39.54 |
ATR14 | INR1.247 (0.12%) |
Volum Korrelasjon
Glenmark Pharmaceuticals Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
AUROPHARMA.NS | 0.938 |
ADORWELD.NS | 0.93 |
ANURAS.NS | 0.923 |
IZMO.NS | 0.914 |
GISOLUTION.NS | 0.907 |
ANMOL.NS | 0.905 |
CAREERP.NS | 0.889 |
KSB.NS | 0.884 |
SETF10GILT.NS | 0.879 |
GTNTEX.NS | 0.876 |
10 Mest negative korrelasjoner | |
---|---|
KOHINOOR.NS | -0.876 |
SEYAIND.NS | -0.867 |
DEEPINDS.NS | -0.855 |
MERCATOR.NS | -0.849 |
STARTECK.NS | -0.835 |
ALLCARGO.NS | -0.808 |
ORTINLAB.NS | -0.807 |
KBCGLOBAL.NS | -0.803 |
SWANENERGY.NS | -0.803 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Glenmark Pharmaceuticals Korrelasjon - Valuta/Råvare
Glenmark Pharmaceuticals Økonomi
Annual | 2022 |
Omsetning: | INR127.25B |
Bruttogevinst: | INR81.88B (64.35 %) |
EPS: | INR10.53 |
FY | 2022 |
Omsetning: | INR127.25B |
Bruttogevinst: | INR81.88B (64.35 %) |
EPS: | INR10.53 |
FY | 2022 |
Omsetning: | INR121.74B |
Bruttogevinst: | INR77.14B (63.37 %) |
EPS: | INR33.37 |
FY | 2021 |
Omsetning: | INR108.06B |
Bruttogevinst: | INR70.62B (65.35 %) |
EPS: | INR34.38 |
Financial Reports:
No articles found.
Glenmark Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR2.50 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR2.50 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.600 | 2002-09-12 |
Last Dividend | INR2.50 | 2023-09-18 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 22 | -- |
Total Paid Out | INR30.90 | -- |
Avg. Dividend % Per Year | 0.37% | -- |
Score | 1.29 | -- |
Div. Sustainability Score | 0.0208 | |
Div.Growth Potential Score | 2.81 | |
Div. Directional Score | 1.416 | -- |
Year | Amount | Yield |
---|---|---|
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR2.00 | 0.38% |
2019 | INR2.00 | 0.29% |
2020 | INR2.50 | 0.72% |
2021 | INR2.50 | 0.50% |
2022 | INR2.50 | 0.48% |
2023 | INR2.50 | 0.59% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RVNL.NS | Dividend Knight | 2023-09-20 | Annually | 6 | 3.08% | |
LSIL.NS | Dividend Junior | 2023-07-17 | Annually | 3 | 0.23% | |
GEOJITFSL.NS | Dividend Knight | 2023-06-30 | Annually | 20 | 2.79% | |
ARVIND.NS | Dividend Junior | 2023-07-21 | Sporadic | 20 | 0.59% | |
THEMISMED.NS | Dividend Junior | 2023-08-31 | Sporadic | 18 | 0.39% | |
ORIENTELEC.NS | Dividend Junior | 2023-07-26 | Semi-Annually | 7 | 0.41% | |
IRFC.NS | Dividend Junior | 2023-09-15 | Annually | 4 | 2.61% | |
CUB.NS | Dividend Junior | 2023-08-11 | Annually | 23 | 0.35% | |
SHRADHA.NS | Dividend Junior | 2023-07-06 | Sporadic | 6 | 0.99% | |
MAPMYINDIA.NS | Dividend Junior | 2023-08-25 | Annually | 3 | 0.13% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0581 | 1.500 | -1.161 | -1.742 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | -0.0742 | 1.500 | -1.935 | -2.90 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 1.901 | 1.000 | -0.407 | -0.407 | [3 - 30] |
operatingCashFlowPerShareTTM | 31.65 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 31.65 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.621 | 1.000 | 2.99 | 2.99 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0740 | 1.000 | -0.520 | -0.520 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 0.0208 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -42.92 | 1.000 | -4.44 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0742 | 2.50 | -1.244 | -2.90 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 31.65 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.231 | 1.500 | 4.23 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 31.65 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.627 | 1.500 | 9.15 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0729 | 1.000 | -0.678 | 0 | [0.1 - 0.5] |
Total Score | 2.81 |
Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.